These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 16215281)

  • 1. Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics.
    Bachmann RF; Schloesser RJ; Gould TD; Manji HK
    Mol Neurobiol; 2005 Oct; 32(2):173-202. PubMed ID: 16215281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics.
    Manji HK; Duman RS
    Psychopharmacol Bull; 2001; 35(2):5-49. PubMed ID: 12397885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers.
    Manji HK; Chen G
    Mol Psychiatry; 2002; 7 Suppl 1():S46-56. PubMed ID: 11986995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translating neurotrophic and cellular plasticity: from pathophysiology to improved therapeutics for bipolar disorder.
    Soeiro-de-Souza MG; Dias VV; Figueira ML; Forlenza OV; Gattaz WF; Zarate CA; Machado-Vieira R
    Acta Psychiatr Scand; 2012 Nov; 126(5):332-41. PubMed ID: 22676371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications.
    Manji HK; Bebchuk JM; Moore GJ; Glitz D; Hasanat KA; Chen G
    J Clin Psychiatry; 1999; 60 Suppl 2():27-39; discussion 40-1, 113-6. PubMed ID: 10073385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular plasticity cascades: genes-to-behavior pathways in animal models of bipolar disorder.
    Einat H; Manji HK
    Biol Psychiatry; 2006 Jun; 59(12):1160-71. PubMed ID: 16457783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lithium, Stress, and Resilience in Bipolar Disorder: Deciphering this key homeostatic synaptic plasticity regulator.
    Machado-Vieira R
    J Affect Disord; 2018 Jun; 233():92-99. PubMed ID: 29310970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Search for a common mechanism of mood stabilizers.
    Harwood AJ; Agam G
    Biochem Pharmacol; 2003 Jul; 66(2):179-89. PubMed ID: 12826261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of the effects of four mood stabilizers in SH-SY5Y cells and in primary neurons.
    Di Daniel E; Mudge AW; Maycox PR
    Bipolar Disord; 2005 Feb; 7(1):33-41. PubMed ID: 15654930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurodevelopment and mood stabilizers.
    Harwood AJ
    Curr Mol Med; 2003 Aug; 3(5):472-82. PubMed ID: 12943000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers.
    Gould TD; Quiroz JA; Singh J; Zarate CA; Manji HK
    Mol Psychiatry; 2004 Aug; 9(8):734-55. PubMed ID: 15136794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The extracellular signal-regulated kinase pathway: an emerging promising target for mood stabilizers.
    Chen G; Manji HK
    Curr Opin Psychiatry; 2006 May; 19(3):313-23. PubMed ID: 16612219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of mood stabilizers as plasticity enhancers in the treatment of neuropsychiatric disorders.
    Gray NA; Zhou R; Du J; Moore GJ; Manji HK
    J Clin Psychiatry; 2003; 64 Suppl 5():3-17. PubMed ID: 12720479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myristoylated alanine-rich C kinase substrate (MARCKS): a molecular target for the therapeutic action of mood stabilizers in the brain?
    Lenox RH; McNamara RK; Watterson JM; Watson DG
    J Clin Psychiatry; 1996; 57 Suppl 13():23-31; discussion 32-3. PubMed ID: 8970502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder.
    Shaltiel G; Chen G; Manji HK
    Curr Opin Pharmacol; 2007 Feb; 7(1):22-6. PubMed ID: 17055337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational polypharmacy in the bipolar affective disorders.
    Post RM; Ketter TA; Pazzaglia PJ; Denicoff K; George MS; Callahan A; Leverich G; Frye M
    Epilepsy Res Suppl; 1996; 11():153-80. PubMed ID: 9294735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression.
    Manji HK; Quiroz JA; Sporn J; Payne JL; Denicoff K; A Gray N; Zarate CA; Charney DS
    Biol Psychiatry; 2003 Apr; 53(8):707-42. PubMed ID: 12706957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective disruption of dopamine D2-receptors/beta-arrestin2 signaling by mood stabilizers.
    Del' Guidice T; Beaulieu JM
    J Recept Signal Transduct Res; 2015 Jun; 35(3):224-32. PubMed ID: 26459714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms underlying mood stabilization in manic-depressive illness: the phenotype challenge.
    Ikonomov OC; Manji HK
    Am J Psychiatry; 1999 Oct; 156(10):1506-14. PubMed ID: 10518159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antipsychotics in the treatment of bipolar disorder.
    Singh J; Chen G; Canuso CM
    Handb Exp Pharmacol; 2012; (212):187-212. PubMed ID: 23129333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.